Our approach is to target unique neoantigens (abnormal mutations and genomic variations produced by cancer cells) from individual patient tumors to develop novel treatments for cancer.
Our technology is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor- specific neoantigen-targeted personalized immunotherapies.
GT-EPIC™ Highlights
We start with a patient’s tumor sample (biopsy specimen) and then sequence the DNA and RNA from the patient tumors. We then identify all targetable neoantigens by comparing the tumor genetic sequences to the patient’s normal genome.
After selecting appropriate mutated sequences to target for each patient, we make the synthetic neoantigen DNA sequences and insert these DNA sequences into a proprietary DNA plasmid. Multiple neoantigen DNA sequences can be inserted into a single plasmid and multiple DNA plasmids can be combined into a patient specific formulation enabling Geneos to deliver all the targetable neoantigens simultaneously.
We manufacture the patient specific neoantigen-coding DNA plasmids under cGMP conditions using a proprietary manufacturing process.
The patient specific formulation is then injected into the patient by a proprietary in vivo electroporation (EP) based delivery system. Geneos has secured a license to the CELLECTRA® EP ‡ delivery technology from INOVIO in the field of personalized therapies for cancer.
The entire manufacturing process from biopsy-to-treatment is accomplished in 6-8 weeks currently. In the future, with better process integration, we can further reduce the manufacturing turnaround time to 3-4 weeks.